Innate Pharma S.A. (LON:0EVI)
1.809
+0.075 (4.33%)
At close: Sep 15, 2025
Innate Pharma Revenue
In the year 2024, Innate Pharma had annual revenue of 20.12M EUR, down -67.36%. Innate Pharma had revenue of 7.78M in the half year ending December 31, 2024, a decrease of -35.66%.
Revenue
20.12M EUR
Revenue Growth
-67.36%
P/S Ratio
8.62
Revenue / Employee
111.17K EUR
Employees
181
Market Cap
143.50M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
HSBC Holdings | 41.03B |
Shell | 198.54B |
Unilever | 51.24B |
Rolls-Royce Holdings | 19.54B |
British American Tobacco p.l.c. | 25.60B |
Rio Tinto Group | 39.22B |
BP p.l.c. | 134.89B |